Compare Novartis with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs BIOCON - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS BIOCON NOVARTIS/
BIOCON
 
P/E (TTM) x 1,953.5 33.6 5,814.8% View Chart
P/BV x 25.9 4.0 647.9% View Chart
Dividend Yield % 1.7 0.2 693.2%  

Financials

 NOVARTIS   BIOCON
EQUITY SHARE DATA
    NOVARTIS
Mar-19
BIOCON
Mar-19
NOVARTIS/
BIOCON
5-Yr Chart
Click to enlarge
High Rs980707 138.6%   
Low Rs600554 108.4%   
Sales per share (Unadj.) Rs198.791.9 216.2%  
Earnings per share (Unadj.) Rs21.016.7 125.5%  
Cash flow per share (Unadj.) Rs22.324.2 92.1%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.30.2 798.1%  
Book value per share (Unadj.) Rs307.5101.6 302.5%  
Shares outstanding (eoy) m24.69600.00 4.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.06.9 57.9%   
Avg P/E ratio x37.737.7 99.9%  
P/CF ratio (eoy) x35.526.1 136.1%  
Price / Book Value ratio x2.66.2 41.4%  
Dividend payout %47.76.0 796.9%   
Avg Mkt Cap Rs m19,508378,330 5.2%   
No. of employees `0000.66.1 9.5%   
Total wages/salary Rs m1,17111,653 10.0%   
Avg. sales/employee Rs Th8,445.48,994.3 93.9%   
Avg. wages/employee Rs Th2,015.71,900.7 106.1%   
Avg. net profit/employee Rs Th891.01,635.3 54.5%   
INCOME DATA
Net Sales Rs m4,90755,144 8.9%  
Other income Rs m7831,444 54.2%   
Total revenues Rs m5,68956,588 10.1%   
Gross profit Rs m12315,883 0.8%  
Depreciation Rs m324,478 0.7%   
Interest Rs m16709 2.2%   
Profit before tax Rs m85812,140 7.1%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3402,123 16.0%   
Profit after tax Rs m51810,026 5.2%  
Gross profit margin %2.528.8 8.7%  
Effective tax rate %39.617.5 226.7%   
Net profit margin %10.618.2 58.0%  
BALANCE SHEET DATA
Current assets Rs m8,05548,228 16.7%   
Current liabilities Rs m1,85030,376 6.1%   
Net working cap to sales %126.432.4 390.6%  
Current ratio x4.41.6 274.2%  
Inventory Days Days4568 65.9%  
Debtors Days Days3486 39.7%  
Net fixed assets Rs m15064,130 0.2%   
Share capital Rs m1233,000 4.1%   
"Free" reserves Rs m7,46957,980 12.9%   
Net worth Rs m7,59260,980 12.4%   
Long term debt Rs m015,766 0.0%   
Total assets Rs m9,824121,924 8.1%  
Interest coverage x54.918.1 303.2%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.5 110.4%   
Return on assets %5.48.8 61.7%  
Return on equity %6.816.4 41.5%  
Return on capital %11.516.8 68.7%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m5815,506 0.4%   
Fx outflow Rs m1,32610,399 12.8%   
Net fx Rs m-1,2695,107 -24.8%   
CASH FLOW
From Operations Rs m-1,94311,546 -16.8%  
From Investments Rs m2,742-7,138 -38.4%  
From Financial Activity Rs m-298-2,417 12.3%  
Net Cashflow Rs m5012,103 23.8%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 2.0 8.4 23.8%  
FIIs % 1.6 10.7 15.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 19.9 108.0%  
Shareholders   41,647 109,995 37.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  NEULAND LABS  PIRAMAL ENTERPRISES  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Apr 13, 2021 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS